HUP9801712A2 - Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása - Google Patents

Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása

Info

Publication number
HUP9801712A2
HUP9801712A2 HU9801712A HUP9801712A HUP9801712A2 HU P9801712 A2 HUP9801712 A2 HU P9801712A2 HU 9801712 A HU9801712 A HU 9801712A HU P9801712 A HUP9801712 A HU P9801712A HU P9801712 A2 HUP9801712 A2 HU P9801712A2
Authority
HU
Hungary
Prior art keywords
cilansetron
stobilizing
racemisation
production
pharmaceutical compositions
Prior art date
Application number
HU9801712A
Other languages
English (en)
Inventor
Ingo Bonnacker
Gernhard Kristen
Hartmut Köhn
Christine Reichel
Original Assignee
Solvay Pharmaceuticals Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh. filed Critical Solvay Pharmaceuticals Gmbh.
Publication of HU9801712D0 publication Critical patent/HU9801712D0/hu
Publication of HUP9801712A2 publication Critical patent/HUP9801712A2/hu
Publication of HUP9801712A3 publication Critical patent/HUP9801712A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány szerinti, hatóanyagként cilansetrőnt vagy savaddícióssóját tartalmazó szilárd és főlyékőny gyógyászati készítményekcilansetrőnracemizálódással szemben történő stabilizálásáhőz elegendőmennyiséggen valamely vízőldható savas adalékanyagőt, éspedig valamelyalábbi anyagőt tartalmaznak: 2-12 szénatőmőt tartalmaz és 1,1-4,8 elsőpKs-értékű egybázisú vagy több-bázisú szerves savak, a fentemlítetttöbb-bázisú szerves savak savanyú sói, és 1,5-7,5 közötti első pKs-értékű gyógyászatilag alkalmas több-bázisú ásványi savak. A találmány tővábbá a fenti savas adalékanyagők cilansetrőnnakgyógyászati készítményekben racemizálódással szemben történőstabilizására történő felhasználására vőnatkőzik. ŕ
HU9801712A 1997-08-01 1998-07-29 Pharmaceutical compositions containing cilansetron stabilized against racemisation, their production and use of stobilizing additive agents HUP9801712A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19733271 1997-08-01
DE19813661A DE19813661A1 (de) 1997-08-01 1998-03-27 Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron

Publications (3)

Publication Number Publication Date
HU9801712D0 HU9801712D0 (en) 1998-09-28
HUP9801712A2 true HUP9801712A2 (hu) 1999-04-28
HUP9801712A3 HUP9801712A3 (en) 2001-08-28

Family

ID=7837672

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801712A HUP9801712A3 (en) 1997-08-01 1998-07-29 Pharmaceutical compositions containing cilansetron stabilized against racemisation, their production and use of stobilizing additive agents

Country Status (29)

Country Link
US (1) US5977127A (hu)
EP (1) EP0895782B1 (hu)
JP (1) JP4324260B2 (hu)
KR (1) KR100515201B1 (hu)
CN (1) CN1117565C (hu)
AR (1) AR010178A1 (hu)
AT (1) ATE283706T1 (hu)
AU (1) AU743043B2 (hu)
BR (1) BR9803730A (hu)
CA (1) CA2244389C (hu)
CZ (1) CZ295072B6 (hu)
DE (2) DE19813661A1 (hu)
DK (1) DK0895782T3 (hu)
DZ (1) DZ2560A1 (hu)
ES (1) ES2234051T3 (hu)
HK (1) HK1017611A1 (hu)
HU (1) HUP9801712A3 (hu)
ID (1) ID20685A (hu)
IL (1) IL125403A (hu)
NO (1) NO323229B1 (hu)
NZ (1) NZ331083A (hu)
PL (1) PL191767B1 (hu)
PT (1) PT895782E (hu)
RU (1) RU2199318C2 (hu)
SK (1) SK284916B6 (hu)
TR (1) TR199801432A3 (hu)
TW (1) TW509570B (hu)
UA (1) UA62924C2 (hu)
ZA (1) ZA986715B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452545B2 (en) * 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
DE60211494T2 (de) * 2001-03-26 2006-10-12 Novartis Ag Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
PL378369A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
MXPA05007381A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para el tratamiento de transtornos funcionales del intestino.
ES2290741T3 (es) * 2003-04-04 2008-02-16 Dynogen Pharmaceuticals Inc. Metodo de tratamiento de trastornos del tracto urinario inferior.
US7820690B2 (en) * 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
CA2733778A1 (en) * 2008-08-14 2010-02-18 Hiroshi Uchida Stabilized pharmaceutical composition
JPWO2021100728A1 (hu) 2019-11-20 2021-05-27

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059491T3 (es) * 1987-06-29 1994-11-16 Duphar Int Res Derivados de indol con anillos condensados.
DE4238553A1 (de) * 1992-11-14 1994-05-19 Kali Chemie Pharma Gmbh Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds

Also Published As

Publication number Publication date
TR199801432A2 (xx) 1999-02-22
CN1117565C (zh) 2003-08-13
CZ295072B6 (cs) 2005-05-18
SK100998A3 (en) 1999-02-11
RU2199318C2 (ru) 2003-02-27
AR010178A1 (es) 2000-05-17
TR199801432A3 (tr) 1999-02-22
JPH1192369A (ja) 1999-04-06
NO983540D0 (no) 1998-07-31
PL327786A1 (en) 1999-02-15
HK1017611A1 (en) 1999-11-26
AU7863098A (en) 1999-02-11
TW509570B (en) 2002-11-11
ATE283706T1 (de) 2004-12-15
EP0895782A2 (de) 1999-02-10
CA2244389C (en) 2008-01-15
CA2244389A1 (en) 1999-02-01
DE59812317D1 (de) 2005-01-05
HUP9801712A3 (en) 2001-08-28
SK284916B6 (sk) 2006-02-02
US5977127A (en) 1999-11-02
CN1207292A (zh) 1999-02-10
NO983540L (no) 1999-02-02
ES2234051T3 (es) 2005-06-16
IL125403A (en) 2001-11-25
NO323229B1 (no) 2007-02-05
CZ236798A3 (cs) 1999-02-17
HU9801712D0 (en) 1998-09-28
JP4324260B2 (ja) 2009-09-02
PT895782E (pt) 2005-02-28
PL191767B1 (pl) 2006-06-30
AU743043B2 (en) 2002-01-17
KR19990023194A (ko) 1999-03-25
UA62924C2 (en) 2004-01-15
BR9803730A (pt) 2000-03-28
ZA986715B (en) 1999-02-04
NZ331083A (en) 2000-01-28
ID20685A (id) 1999-02-18
DK0895782T3 (da) 2005-01-03
DZ2560A1 (fr) 2003-02-15
DE19813661A1 (de) 1999-02-04
EP0895782A3 (de) 2001-01-31
KR100515201B1 (ko) 2005-12-09
EP0895782B1 (de) 2004-12-01
IL125403A0 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
CY1105437T1 (el) Συνθεσεις πepιεχοντας διφωσφονικα οξεα
NO20022264L (no) Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav
EA199700201A1 (ru) Парентеральные фармацевтические композиции, содержащие алкиламмониевые соли 2-арилпропиновых кислот
HUP9801712A2 (hu) Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása
ES2194679T3 (es) Composiciones cosmeticas que contienen creatina, carnitina y/o acido piruvico.
MY130441A (en) Solutions containing epinastin
ES2149305T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
SE8900828L (sv) Antivirala och immunstimulerande farmaceutiska kompositioner samt foerfarande foer framstaellning av desamma
FI944823A0 (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
MXPA02011389A (es) Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y aplicacion.
WO2002007677A3 (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
KR950031084A (ko) 국소용 진양(鎭洋) 조성물
KR930023338A (ko) 데포우 제제
DE69809435D1 (de) Inhibitor- und konservierungsmittelzusammensetzung
ES2000681A6 (es) Un procedimiento para preparar nuevos compuestos de bencilpiperazina
PT97164A (pt) Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham
CA2534259A1 (en) Glycyrrhizin high-concentration preparation
EA200200211A1 (ru) Фармацевтическая композиция и ее приготовление
NZ505080A (en) Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid
HUP9601527A2 (hu) Véralvadásgátló hatású peptid-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
PT986390E (pt) Composicoes farmaceuticas que contem cicloridrato de cinchonina
DE69812059D1 (de) Beta,beta-disubstituierte Derivate von 9-Deoxo-9a-N-ethenyl-9a-aza-9a-homoerythromycin A
KR870001153A (ko) 디페녹시에틸아민 유도체가 함유된 약제조성물 및 그의 생산방법
WO2002081462A8 (en) Aminoflavone compounds, compositions, and methods of use thereof

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished